2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).
Eur Heart J Cardiovasc Imaging
; 23(10): e333-e465, 2022 09 10.
Article
em En
| MEDLINE
| ID: mdl-36017575
Palavras-chave
Amyloid light-chain cardiac amyloidosis; Androgen deprivation therapy; Anthracycline; Arrhythmias; Atrial fibrillation; Biomarkers; Cancer; Cancer survivors; Carcinoid syndrome; Cardiac magnetic resonance; Cardiac tumour; Cardio-oncology; Cardiotoxicity; Chemotherapy; Coronary artery disease; Echocardiography; Fluoropyrimidine; Guidelines; Haematopoietic stem cell transplantation; Heart failure; Hormone therapy; Hypertension; Immunotherapy; Ischaemic heart disease; Myocarditis; Pericardial disease; Proteasome inhibitors; Pulmonary hypertension; QTc prolongation; Radiotherapy; Risk stratification; Strain; Thrombosis; Trastuzumab; Valvular heart disease; Vascular endothelial growth factor inhibitors (VEGFi); Venous thromboembolism
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Radioterapia (Especialidade)
/
Hematologia
/
Neoplasias
/
Antineoplásicos
Tipo de estudo:
Guideline
/
Risk_factors_studies
Limite:
Humans
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article